MMI-0100(Cat No.:I043793)is a cell-penetrating peptide inhibitor designed to target and block the interaction between small GTPases, specifically Ras and Raf, which are involved in the MAPK signaling pathway. This pathway regulates cell growth, survival, and differentiation, and its dysregulation is associated with various cancers. By inhibiting Ras-Raf interaction, MMI-0100 aims to disrupt aberrant signaling in tumor cells, potentially reducing cancer cell proliferation and survival. It is being investigated in preclinical studies for its potential as a targeted cancer therapy, especially for cancers driven by Ras-Raf pathway activation.